Phase I Study of Lenalidomide in Patients With Acute Leukemia
Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Lenalidomide is a drug that alters the immune system and it may also be directly toxic to
tumor. Therefore, in theory, it may reduce or prevent the growth of cancer cells or directly
kill them. We will be studying how lenalidomide can be used to decrease bone marrow blast
cells in preparation for a bone transplant.